1
|
Prowse CV, Boffa MC, Guthrie C, Pepper DS. In Vitro Thrombogenicity Tests of Factor IX Concentrates. II: Effects of Phospholipids and Heparin. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657036] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryMeasurement of the total phospholipid (and that portion active in coagulation) in factor IX concentrates revealed no correlation with in vitro tests of potential thrombogenicity, except in the case of the recalcification time and the thrombin generation test which may detect coagulant phospholipid as well as the presence of thrombogenic enzymes. This is probably due to separation of the prothrombin complex proteins from most phospholipid during ion-exchange chromatography. Although low levels of phospholipid remain in the final product these are apparently insufficient to effect appreciable activation of factor IX concentrates despite low levels of antithrombin III.Two tests which measure the formation of thrombin and factor Xa after recalcification of concentrates were affected by the addition of exogenous phospholipid. However this is a relative effect such that differences are quantitative rather than qualitative.Heparin addition during production of factor IX concentrate was found to have only minor effects on the results of in vitro thrombogenicity tests of the final product. This was confirmed in the laboratory by incubation of unheparinised products with heparin for periods of up to 6 hr.
Collapse
Affiliation(s)
- C V Prowse
- The South East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh
| | - M C Boffa
- Centre National de Transfusion Sanguine, Alexandre-Cabanel, Paris
- The South East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh
| | - C Guthrie
- Commonwealth Serum Laboratories, Parkville, Australia
- The South East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh
| | - D S Pepper
- The South East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh
| |
Collapse
|
2
|
Abstract
SummaryThe effect of negatively-charged polymers, used in some artificial devices, on plasma clotting and kinin systems was studied in vitro using polyelectrolyte complexes.Contact activation was observed as an immediate, transient and surface-dependent phenomenon. After incubation of the plasma with the polymer a small decrease of factor XII activity was noticed, which corresponded to a greater reduction of prekallikrein activity and to a marked kinin release. No significant decrease of factor XII, prekallikrein, HMW kininogen could be detected immunologically. Only the initial contact of the plasma with the polyelectrolyte lead to activation, subsequently the surface became inert.Beside contact activation, factor V activity also decreased in the plasma. The decrease was surface and time-dependent. It was independent of contact factor activation, and appeared to be related to the sulfonated groups of the polymer. If purified factor V was used instead of plasma factor V, inactivation was immediate and not time-dependent suggesting a direct adsorption on the surface. A second incubation of the plasma-contacted polymer with fresh plasma resulted in a further loss of Factor V activity.
Collapse
Affiliation(s)
- M C Boffa
- The Centre National de Transfusion Sanguine, Paris
| | - B Dreyer
- The Rhône Poulenc Research Center, Vitry-sur-Seine, Saint-Fons, France
| | - C Pusineri
- The Rhône Poulenc Research Center, Saint-Fons, France
| |
Collapse
|
3
|
Steinbuch M, Péjaudier L, Kichenin V, Boffa MC. Studies on Prothrombin Complex Concentrates Contact Factors, Complement Components and Proteinase Inhibitors. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe behaviour of contact factors, complement components and antiproteases during the preparation of prothrombin complex concentrates by adsorption of the clotting components on DEAE-Sephadex has been studied.The pro-enzymes: factors XII, XI and prekallikrein were removed by pre-elution in function of the salt concentration. In contrast, high molecular weight kininogen was considerably enriched in PCC preparations. C4 of the complement system displayed an analogous behaviour. Cls reached a 4-5 fold plasma concentration but C3 only 30% of the normal plasma level.The prothrombin complex concentrate contained no antithrombin III nor α2M nor α2 antiplasmin but a three fold plasma concentration of Cl-inactivator and a 15 fold increase of inter-α- trypsin inhibitor.NAPTT (Non Activated Partial Thromboplastin Time) ratios did not seem to be in accordance with either the presence or the absence of contact enzymes. Moreover 0.20 M NaCl appeared as the minimal pre-elution molarity necessary to ensure a NAPTT ratio above thrombogenic values.Molecular alteration of high molecular weight kininogen and C4 was observed and its significance discussed. Complex formation between C1-inactivator and proteases was shown to be another sign of undesirable proteolytic events.
Collapse
Affiliation(s)
- M Steinbuch
- The Laboratoire de Biochimie, C.N.T.S., Paris, France
| | - L Péjaudier
- The Laboratoire de Biochimie, C.N.T.S., Paris, France
| | - V Kichenin
- The Laboratoire de Biochimie, C.N.T.S., Paris, France
| | - M C Boffa
- The les Ulis et Laboratoire de Recherche en Hémostase et Thrombose, C.N.T.S., Paris, France
| |
Collapse
|
4
|
Abstract
SummaryA solid Heparin-PMMA copolymer has been synthetized by a radical polymerization of methyl methacrylate from oxidative reaction initiated by Ce4+ ions in the presence of heparin. Covalently linked heparin was 10% of copolymer weight. The antithrombin activity of the copolymer corresponded to 1% of grafted heparin. PMMA sequence of the copolymer played the leading role in fibrinogen, immunoglobulins, transferrin and albumin adsorption. These proteins adsorbed on the copolymer, showed different competitive desorption pattern in the presence of whole plasma: fibrinogen presented the highest degree of affinity for the copolymer. The heparin part of the copolymer was responsible for antithrombin III adsorption and for decrease of factor V activity. Active antithrombin III was eluted. An inactivation of factor V in plasma was observed using high concentrations of soluble heparin. This result suggested that copolymer heparin chains, even devoid of antithrombin activity, were involved in this inactivation. With Heparin-PMMA copolymer, plasma clotting pro-enzymes behaved differently than on heparin-sepharose copolymer: disappearance of factor XI activity, decrease in prekallikrein activity and activation of factor IX were observed. PMMA sequences were responsible for factor IX activation.
Collapse
Affiliation(s)
- M C Boffa
- Laboratoires d’Hémostase et de Biochimie Moléculaire, Centre National de Transfusion Sanguine 75 739 Paris Cedex 15 France
- M. D., INSERM
| | - D Labarre
- Laboratoires d’Hémostase et de Biochimie Moléculaire, Centre National de Transfusion Sanguine 75 739 Paris Cedex 15 France
- Laboratoire de Recherche sur les Macromolécules associeau CNRS 94430 Villetaneuse, France
| | - M Jozefowicz
- Laboratoires d’Hémostase et de Biochimie Moléculaire, Centre National de Transfusion Sanguine 75 739 Paris Cedex 15 France
- Laboratoire de Recherche sur les Macromolécules associeau CNRS 94430 Villetaneuse, France
| | - G A Boffa
- Laboratoires d’Hémostase et de Biochimie Moléculaire, Centre National de Transfusion Sanguine 75 739 Paris Cedex 15 France
| |
Collapse
|
5
|
Bellucci S, Ignatova E, Jaillet N, Boffa MC. Platelet Hyperactivation in Patients with Essential Thrombocythemia Is not Associated with Vascular Endothelial Cell Damage as Judged by the Level of Plasma Thrombomodulin, Protein S, PAI-1, t-PA and vWF. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649661] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe occurrence of thrombotic events remains an important clinical problem in Essential Thrombocythemias (ET). Thus, hemostatic, fibrinolytic and vascular status was investigated in 16 patients (5 males and 11 females) with ET. Among them five presented thromboses in their past history. Platelet hyperactivation, as evidenced by a mean three-fold increase in plasma betathromboglobulin (βTG), was observed in 13 among 16 patients; surprisingly this activation was present even when the platelet count was normal (in two patients) or subnormal, below 600 x 109/1 (in 11 patients). The mean value was 104 ± 57 IU/ml significantly different from that of normal controls (35 ± 16.5 IU/ ml) (p <0.001). An artefactual in vitro platelet activation was ruled out by the concomitant measurement of platelet factor, 4 (PF4). D-dimers fibrin degradation products (D-Di FDP) were normal in all patients. Vascular endothelial cell function parameters were not markedly modified. The mean value of plasma thrombomodulin ™ was found slightly but not significantly increased (60.1 ±4.9 ng/ml versus 49.1 ± 10.0 ng/ml in controls). The values of plasma TM correlated neither with that of the platelet count nor with that of plasma βTG or plasma PF4. The mean values of plasma protein S, von Willebrand factor (vWF), plasminogen activator inhibitor type 1 (PAI-1), tissue plasminogen activator (tPA) were normal and were not correlated neither with that of plasma TM nor with that of plasma βTG. In spite of a significant increase in vWF in two patients who presented peripheral thromboses, the markers of vascular endothelial cell function were not significantly different in patients having presented or not thromboses. Thus, in ET, these data showed the presence of platelet hyperactivation, even in patients in remission; it was not associated with vascular endothelial cell damage which might account for a greater risk of thrombosis.
Collapse
Affiliation(s)
- S Bellucci
- Laboratory of Hematology, Hôpital Lariboisière, Paris, France
| | - E Ignatova
- Laboratory of Hematology, Hôpital Lariboisière, Paris, France
| | - N Jaillet
- Laboratory of Hematology, Hôpital Lariboisière, Paris, France
| | - M C Boffa
- INSERM U 353, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
6
|
Alessi MC, Boffa MC, Menart C, Aillaud MF, Parrot G, Juhan-Vague I. Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646304] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M C Alessi
- Laboratory of Hematology CHU Timone, Marseille, France
| | - M C Boffa
- INSERM U150 Hôpital Saint Louis Paris, France
| | - C Menart
- Laboratory of Hematology CHU Timone, Marseille, France
| | - M F Aillaud
- Laboratory of Hematology CHU Timone, Marseille, France
| | - G Parrot
- Laboratory of Hematology CHU Timone, Marseille, France
| | - I Juhan-Vague
- Laboratory of Hematology CHU Timone, Marseille, France
| |
Collapse
|
7
|
Rodríguez-Pintó I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R, Cervera R, Espinosa G, Rodríguez-Pintó I, Shoenfeld Y, Erkan D, Piette JC, Jacek M, Roca B, Tektonidou M, Moutsopoulos H, Boffa J, Chapman J, Stojanovich L, Veloso MP, Praprotnik S, Traub B, Levy R, Daryl T, Daryl T, Boffa MC, Makatsaria A, Ruano M, Allievi A, You W, Khamastha M, Hughes S, Menendez Suso J, Pacheco J, Boriotti MF, Dias C, Pangtey G, Miller S, Policepatil S, Larissa L, Marjatta S, Carolyn S, Noortje T, Reiner K, Arteaga S, Leilani T, Langsford D, Niedzwiecki M, Queyrel V, Moroti-Constantinescu R, Romero C, Jeremic K, Urbano A, Hurtado-García R, Kumar Das A, Costedoat-Chalumeau N, Yngvar F, Gomez-Puerta JA, de Meigs E, Smith JP, Zakharova E, Nayer A, Douglas W, Lyndsey R, Blanco V, Vicent C, Natalya K, Damian L, Valentini E, Giula B, Casal Moura M, Araújo Loperena O, Ritter Susan Y, Guettrot Imbert G, Almasri H, Hospach T, Mouna B, Robles A, Wilson H, Guisado P, Ruiz R, Rodriguez J. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford) 2018; 57:1264-1270. [DOI: 10.1093/rheumatology/key082] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Revised: 02/28/2018] [Indexed: 01/19/2023] Open
Affiliation(s)
| | - Gerard Espinosa
- Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain
| | - Doruk Erkan
- Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, New York, NY, USA
| | - Yehuda Shoenfeld
- Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel
| | - Ricard Cervera
- Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Motta M, Boffa MC, Tincani A, Avcin T, De Carolis S, Lachassinne E. Follow-up of babies born to mothers with antiphospholipid syndrome: Preliminary data from the European neonatal registry. Lupus 2012; 21:761-3. [DOI: 10.1177/0961203312446387] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In this review preliminary data on the follow-up of 141 babies born to mothers with antiphospholipid syndrome are reported. In spite of maternal treatment, the rate of both preterm delivery and low birth weight were 16 and 17%, respectively. At birth, no clinical evidence of perinatal thrombosis was observed. Placental transfer of antiphospholipid antibodies occurred in 20, 25 and 43% of cases for lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies, respectively. At 24 months of follow-up, four children showed behaviour abnormalities suggesting the possible need for long-term neurological evaluation in this clinical setting.
Collapse
Affiliation(s)
- M Motta
- Neonatology and Neonatal Intensive Care Unit, Children’s Hospital of Brescia, Italy
| | - MC Boffa
- Laboratoire d’Hematologie, Hôpital Jean-Verdier, Bondy, France
| | - A Tincani
- Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy
| | - T Avcin
- Allergology, Rheumatology and Clinical Immunology, University Children’s Hospital Ljubljana, University Medical Center, Ljubljana, Slovenia
| | - S De Carolis
- Obstetrics and Gynecology, Catholic University, Roma, Italy
| | | |
Collapse
|
9
|
Motta M, Lachassinne E, Boffa MC, Tincani A, Avcin T, De Carolis S, Aurousseau MH, Le Toumelin P, Lojacono A, De Carolis MP, Chirico G. European registry of infants born to mothers with antiphospholipid syndrome: preliminary results. Minerva Pediatr 2010; 62:25-27. [PMID: 21089714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The registry is an European, multicentre, prospective and longitudinal study which follows a cohort of children born to mothers with antiphospholipid syndrome (APS). In this article we report preliminary results obtained from 138 mothers and 141 babies (three twin pregnancies). At birth, 16.3% of neonates were less than 37 weeks of gestation and 17% were low birth weight; in addition, 11.3% of neonates were small for gestational age. No cases of neonatal thrombosis were observed. During follow-up period five children showed behavioral abnormalities. A long term clinical follow-up will be necessary to evaluate the neuropsychological development of these children.
Collapse
Affiliation(s)
- M Motta
- Neonatology and Neonatal Intensive Care, Children's Hospital of Brescia, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Boffa MC, Aurousseau MH, Lachassinne E, Dauphin H, Fain O, Le Toumelin P, Uzan M, Piette JC, Derenne S, Boinot C, Avcin T, Motta M, Faden D, Tincani A. European register of babies born to mothers with antiphospholipid syndrome. Lupus 2004; 13:713-7. [PMID: 15485110 DOI: 10.1191/0961203304lu1089oa] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
This prospective multicentric register was initiated by the European Forum of Antiphospholipid Antibodies (APL) in 2003 after approval by local ethic committees. This register allows the investigation of infants after written informed parental consent. It collects mothers' clinical pattern of antiphospholipid syndrome (APS), course and outcome of pregnancy, treatment and immunological status. For the babies, clinical and immunological examinations are performed at birth; neurodevelopmental conditions followed up to five years. A re-evaluation of lupus anticoagulant (LA), anticardiolipin (ACL) or other antibodies will be done if they are positive at birth to follow their kinetics. A descriptive and a case control study of babies with versus without APL at birth will be possible after the inclusion of 300 cases.
Collapse
Affiliation(s)
- M C Boffa
- Department of Internal Medicine, Hôpital de la Pitié, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860-2. [PMID: 15456509 DOI: 10.1111/j.1538-7836.2004.00910.x] [Citation(s) in RCA: 105] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, Font J, Zaech J, Cervera R, Piette JC, Boffa MC, Khamashta MA, Bertolaccini ML, Hughes GRV, Youinou P, Meroni PL, Pengo V, Alves JD, Tincani A, Szegedi G, Lakos G, Sturfelt G, Jönsen A, Koike T, Sanmarco M, Ruffatti A, Ulcova-Gallova Z, Praprotnik S, Rozman B, Lorber M, Vriezman VB, Blank M. Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2004; 23:377-83. [PMID: 14601646 DOI: 10.1023/a:1025321617304] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Two-hundred ninety five patients with the antiphospholipid syndrome (APS) were studied for the presence of antibodies against six anti-beta2GPI-related peptides Abs. The prevalence of a wide spectrum of clinical and laboratory parameters of APS was evaluated in all patients, and correlated with the presence of each anti-beta2GPI peptide antibody. The rates of the various antipeptides Abs ranged from 18.0 to 63.7%. Altogether, 87.1% of the patients had antibody reactivity against at least one of the six beta2GPI-related peptides. A high degree of simultaneous reactivity against several beta2GPI-peptides was found. Positive and negative correlations were found between several antipeptides Abs and the rates of thrombosis and fetal loss. Our results point to a heterogeneous activity of antiphospholipid Abs in APS patients, directed, often concurrently, against various epitopes of the beta2GPI molecule. Evaluation of APS patients for the presence of specific antipeptides Abs may be of a value in predicting the risk for future thrombotic and obstetrical complication, as well as for specific therapeutic purposes.
Collapse
Affiliation(s)
- Y Shoenfeld
- Department of Medicine "B", Sheba Medical Center, Tel-Hashomer, Israel.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12:530-4. [PMID: 12892393 DOI: 10.1191/0961203303lu394oa] [Citation(s) in RCA: 522] [Impact Index Per Article: 24.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The term 'catastrophic' antiphospholipid syndrome (APS) is used to define an accelerated form of APS resulting in multiorgan failure. Although catastrophic APS patients represent less than 1% of all patients with APS, they are usually in a life-threatening medical situation that requires high clinical awareness. The careful and open discussion of several proposals by all participants in the presymposium workshop on APS consensus, held in Taormina on occasion of the 10th International Congress on aPL and chaired by Munther A Khamashta and Yehuda Shoenfeld (29 September 2002), has allowed the acceptation of a preliminary set of classification criteria. On the other hand, the optimal management of catastrophic APS must have three clear aims: to treat any precipitating factors (prompt use of antibiotics if infection is suspected, amputation for any necrotic organ, high awareness in patients with APS who undergo an operation or an invasive procedure), to prevent and to treat the ongoing thrombotic events and to suppress the excessive cytokine 'storm'. Anticoagulation (usually intravenous heparin followed by oral anticoagulants), corticosteroids, plasma exchange, intravenous gammaglobulins and, if associated with lupus flare, cyclophosphamide, are the most commonly used treatments for catastrophic APS patients.
Collapse
Affiliation(s)
- R A Asherson
- Rheumatic Diseases Unit, University of Cape Town School of Medicine, Cape Town, South Africa
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Alarcón-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, Shoenfeld Y, Wilson W, Roubey R. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003; 12:499-503. [PMID: 12892387 DOI: 10.1191/0961203303lu388oa] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Hypothetical circumstances that may require prophylaxis for a potential antiphospholipid syndrome (primary prophylaxis), or in some instances when there already had been some manifestations ofthe syndrome (secondary prophylaxis), were presented to a panel of experts for their consideration on potential prophylactic intervention. These were subsequently presented to the participants in the First International Consensus on Treatment of the Antiphospholipid Syndrome. In most instances there was consensus in adding low dose aspirin, an exception being aspirin allergy when other antiaggregants could be used in nonpregnant subjects. General measures to prevent thrombosis and other vasoprotective actions should also be provided. Higher risk of fetal loss or thrombosis called for anticoagulation with coumadin in nonpregnant subjects or subcutaneous low molecular weight heparin in pregnant ones. When indicated, prophylaxis of the antiphospholipid syndrome should be provided in systemic lupus erythematosus patients who are being treated for their disease. In no instance should corticosteroids or immunosuppresants be given as prophylactic of an antiphospholipid syndrome.
Collapse
Affiliation(s)
- D Alarcón-Segovia
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico DF, Mexico.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations--a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86:575-83. [PMID: 11522006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Despite the widely recognized practical importance of anticardiolipin (aCL) ELISA, the reliability of this test has been recently discussed. In order to investigate this area on European scale, we sent to 30 experienced centers a questionnaire focusing on the diagnostic procedures applied to patients with antiphospholipid syndrome (APS) and on the detailed protocols used to perform aCL. Anticardiolipin ELISA was found to be the most frequently performed test in patients with suspected APS, but significant difference was shown among the various protocols. The cross-laboratory multiple examination of ten serum samples evaluated independently by the 24 centers pointed out the difficulty in getting comparable results. Therefore a "consensus" protocol was derived from the aCL methods giving the best performance. The materials and reagents necessary to perform the "consensus" method, including, as putative standards, one IgG and one IgM monoclonal antibody (HCAL and EY2C9) were distributed to 19 Centers. The results of one IgG and one IgM aCL high positive sera measured in serial dilutions were compared. A progressive decrease in the variability of the values obtained for a given sample appeared evident when all the laboratories used the same standard, in their own in-house ELISA and even more in the "consensus" ELISA. Our data show that aCL ELISA standardization is necessary in order to obtain comparable results in different laboratories.
Collapse
Affiliation(s)
- A Tincani
- Clinical Immunology Unit, Brescia Hospital, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Praprotnik S, Blank M, Levy Y, Tavor S, Boffa MC, Weksler B, Eldor A, Shoenfeld Y. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 2001; 13:203-10. [PMID: 11157853 DOI: 10.1093/intimm/13.2.203] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease of an unknown etiology, characterized by consumptive thrombocytopenia, microangiopathic hemolytic anemia, fever and acute thrombotic complications, especially within the cerebral circulation. Although anti-endothelial cell antibodies (AECA) have occasionally been shown to be present in TTP, their role in the pathogenesis of the disease has never been ascertained. In the current study we demonstrated the pathogenic activity of affinity-purified anti-endothelial cell F(ab)2 antibodies (AECA/TTP) from four consecutive patients with active TTP. These AECA/TTP bound to and activated only microvascular endothelial cells (EC) and not large vessel EC. The specificity of AECA/TTP binding to microvascular EC was confirmed by competition assay employing membranes derived from small and large vessels EC. Activation included enhanced IL-6 and von Willebrand factor release from the EC followed by increased expression of adhesion molecules P-selectin, E-selectin and vascular cell adhesion molecule-1 on the EC, as evaluated by ELISA. Increased expression of adhesion molecules was followed by an increase in monocyte adhesion to EC. The level of soluble thrombomodulin (TM) also increased in the culture medium of activated microvascular EC upon exposure to AECA/TTP antibodies and was directly correlated to a decrease in cell-associated TM. Our data suggest that AECA/TTP directed against microvascular EC could play a pathogenic role in the development of endothelial injury in TTP that leads to thrombosis.
Collapse
Affiliation(s)
- S Praprotnik
- Research Unit of Autoimmune Diseases and Department Medicine B, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Shoenfeld Y, Praprotnik S, Levy Y, Tavor S, Boffa MC, Barkai G, Eldor A, Blank M. Pathogenic anti-endothelial cell antibodies: classification to anti-microvascular EC and anti-macrovascular EC antibodies. Isr Med Assoc J 2000; 2 Suppl:24-5. [PMID: 11344863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- Y Shoenfeld
- Center for Autoimmune Diseases, Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Tincani A, Balestrieri G, Allegri F, Cinquini M, Vianelli M, Taglietti M, Sanmarco M, Ichikawa K, Koike T, Meroni P, Boffa MC. Overview on anticardiolipin ELISA standardization. J Autoimmun 2000; 15:195-7. [PMID: 10968908 DOI: 10.1006/jaut.2000.0399] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- A Tincani
- Clinical Immunology Unit, Brescia Hospital, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Piette JC, Boffa MC. [Diagnostic value of antiphospholipid antibody assays]. Presse Med 2000; 29:845. [PMID: 10827793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
|
21
|
Abstract
INTRODUCTION Thromboembolic venous disease, which includes both peripheral venous thrombosis and pulmonary embolism, is a frequent disorder in patients with cancer. Although thromboembolic manifestations may precede the diagnosis of cancer, the value of extensive clinical search for potential underlying cancer when faced with venous thromboembolic manifestations has not been demonstrated. CURRENT KNOWLEDGE AND KEY POINTS Clinical and biological studies have demonstrated that acquired abnormalities in blood hemostasis, especially procoagulant factors, account for the onset of thromboembolic manifestations in patients with cancer. Classical anticoagulant therapy is associated with low efficacy and tolerance in patience with cancer who are at high risk for hemorrhagic complications and recurrence of thromboembolic disease. FUTURE PROSPECTS AND PROJECTS Recent data suggest the value of anticoagulant therapy using either low molecular weight heparin or warfarin at low doses (INR < 2) according to the specific surgical or medical context.
Collapse
Affiliation(s)
- C Sauve
- Service de médecine interne, hôpital Saint-Louis, Paris, France
| | | | | | | |
Collapse
|
22
|
Sotto A, Assens C, Berard M, Jourdan J, Boffa MC. Plasma thrombomodulin level is correlated with those of the soluble interleukin-2 receptor and hepatic cytolysis markers in patients with Mediterranean spotted fever. Thromb Haemost 1999; 82:1769-70. [PMID: 10613670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
23
|
Menashi S, Aurousseau MH, Gozin D, Daffos F, D'Angelo A, Forestier F, Boffa MC. High levels of circulating thrombomodulin in human foetuses and children. Thromb Haemost 1999; 81:906-9. [PMID: 10404765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Thrombomodulin (TM) is an endothelial cell surface proteoglycan with anticoagulant functions, also implicated in cell proliferation, cell-cell adhesion and differentiation. In this study we determined circulating plasma TM (pTM) levels in human foetuses at different stages of pregnancy, at birth and in childhood. TM levels increased with gestational age, the median level reaching a peak of approximately 165 ng/ml between the 23rd and 26th week, thereafter decreasing gradually, reaching a value of 108 ng/ml at birth. pTM continues to decrease progressively during childhood, reaching in the 5-15 years group a median of 56 ng/ml which approaches the adult value. The pTM peak was statistically significant and represents a specific foetal phenomenon as it was independent of the corresponding maternal values. As a whole, the pTM pattern during foetal maturation appears totally different from that of protein C, prothrombin and other coagulation activators and inhibitors and thus, TM may play in the foetus another role in addition to its well-known anticoagulant function.
Collapse
Affiliation(s)
- S Menashi
- U353 INSERM, Hôpital Saint Louis, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
24
|
Rabhi-Sabile S, Steiner-Mosonyi M, Pollefeyt S, Collen D, Pouvelle B, Gysin J, Boffa MC, Conway EM. Plasmodium falciparum-infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin. Thromb Haemost 1999; 81:815-21. [PMID: 10365758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The pathophysiologic events leading to organ damage in Plasmodium falciparum malaria infections involve adhesion and sequestration of parasite-infected erythrocytes (PRBC) to the vascular endothelium and syncytiotrophoblast. Several potential receptors to which the PRBCs may bind have recently been identified, one of which is thrombomodulin (TM). TM has been implicated particularly in mediating sequestration of P. falciparum-infected erythrocytes in the placenta and brain, two sites of disease associated with high morbidity. In order to establish that binding of parasite-infected red blood cells to TM is dependent on its containing chondroitin-4-sulfate (CSA), we have mutated the CSA-attachment site of murine TM, and expressed this mutant form (TMsergly) in COS-7 cells. In cytoadhesion assays, we demonstrate that, in contrast to wild-type TM which contains CSA and supports the adhesion of 1466 PRBCs/mm2, TMser-gly does not contain CSA and adhesion of PRBCs to those cells expressing TMser-gly is entirely abrogated (200 PRBCs/mm2). These studies further confirm that the CSA of TM may play a role in the pathophysiology of malaria by providing a binding site for PRBCs.
Collapse
|
25
|
Abstract
Thrombomodulin (TM), a high affinity thrombin receptor present on endothelial cell membrane, plays an important role as a natural anticoagulant. It acts as a cofactor of thrombin-catalyzed activation of protein C, and inhibits the procoagulant functions of thrombin. TM is also located in other cells (keratinocytes, osteoblasts, macrophages,...) where it might be involved in cell differentiation or in inflammation. In the presence of cytokines, activated neutrophils and macrophages, endothelial TM is cleaved enzymatically, releasing soluble fragments which circulate in the blood and are eliminated in urine. Plasma TM level (pTM) can be measured using a two-site enzyme-linked immunosorbent assay (ELISA). pTM level is regarded as a molecular marker reflecting injury of endothelial cells. It is often increased in case of diffuse endothelial damage as in disseminated intravascular coagulation, diabetic microangiopathy, Plasmodium falciparum and rickettsial infections. pTM is also a predictive marker of hypertensive complications in pregnancy. In several systemic inflammatory diseases, pTM levels are correlated to the activity of the disease.
Collapse
Affiliation(s)
- M C Boffa
- INSERM U 353, Institut d'Hématologie, Hôpital Saint-Louis, Paris, France.
| | | |
Collapse
|
26
|
Eschwège V, Darnige L, Piette JC, Boffa MC. European Forum on Antiphospholipid Antibodies: report on the first meeting, 10-11 October 1997, Hôpital Saint-Louis, Paris. Lupus 1998; 7:439-44. [PMID: 9796845 DOI: 10.1191/096120398678920415] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- V Eschwège
- Service d'Hématologie Biologique, Hôpital A. Béclère, Clamart, France
| | | | | | | |
Collapse
|
27
|
Boffa MC, Valsecchi L, Fausto A, Gozin D, Vigano' D'Angelo S, Safa O, Castiglioni MT, Amiral J, D'Angelo A. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost 1998; 79:1092-5. [PMID: 9657429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
In a prospective longitudinal study, 130 primigravidae at risk for preeclampsia were examined and plasma sampling performed in 45 of them. Plasma thrombomodulin (pTM) was sequentially measured at weeks 12, 24 and 32 of gestation and after delivery in 20 primigravidae who developed either mild preeclampsia (n = 8) or gestational hypertension (n = 12) between weeks 32 and 39 of gestation and in 25 (age-matched) primigravidae who had uneventful pregnancies. pTM elevations were not observed until week 32 in uneventful pregnancies, but were present by week 24 (p = 0.002) in patients who later developed hypertensive complications. A net individual pTM increase > or = 4.2 ng/ml between weeks 12 and 24 (more than 8 times that of normotensive primigravidae) and/or pTM level > or = 47.5 ng/ml at week 32 predicted the development of hypertensive complications with 80% accuracy. Serial pTM determinations can be useful to select pregnancies who may benefit from early pharmacological intervention.
Collapse
Affiliation(s)
- M C Boffa
- INSERM Unité 353, Hôpital Saint-Louis, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Généreau T, Peyri N, Berard M, Chérin P, Cabane J, Lehoang P, Guillevin L, Herson S, Boffa MC. Human neutrophil elastase in temporal (giant cell) arteritis: plasma and immunohistochemical studies. J Rheumatol 1998; 25:710-3. [PMID: 9558173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Few enzymes are able to attack the internal elastic lamina, which is destroyed in temporal arteritis (TA). Because human neutrophil elastase (HNE) is one of these, its role in the pathogenesis of TA was examined in patients undergoing temporal artery biopsy for suspected TA. METHODS Over a 6 month period, 33 patients undergoing temporal artery biopsy were prospectively included in the study. TA was diagnosed in 15 patients; 9 of them had positive temporal artery biopsy. The other 18 patients made up the non-TA group. Nineteen healthy age matched subjects (mean age 74 +/- 9 yrs) served as controls. Levels of plasma HNE bound to alpha1-antitrypsin (pHNE-alpha1AT) were measured by ELISA. The presence of HNE in the temporal artery wall of 7 TA and 7 non-TA patients was evaluated immunohistochemically. RESULTS Age, neutrophil counts, and erythrocyte sedimentation rates were similar in TA and non-TA patients. The mean pHNE-alpha1AT concentration in the TA group (84 +/- 20 microg/l) was significantly higher (p < 0.001) than in the non-TA group (51 +/- 26 microg/l) or in healthy controls (52 +/- 23 microg/l). The diagnostic sensitivity of pHNE-alpha1AT > 50 microg/l was 100%. Immunohistochemistry detected no HNE within the temporal artery wall of any patient. CONCLUSION High levels of pHNE-alpha1AT were associated with TA. Our preliminary results indicate this could be a diagnostic marker for TA. Further studies are needed to confirm its reliability. Because HNE was not detected locally, no conclusions can be drawn as to its pathogenic role in TA.
Collapse
Affiliation(s)
- T Généreau
- INSERM U353, Hôpital St-Louis, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Gysin J, Pouvelle B, Le Tonquèze M, Edelman L, Boffa MC. Chondroitin sulfate of thrombomodulin is an adhesion receptor for Plasmodium falciparum-infected erythrocytes. Mol Biochem Parasitol 1997; 88:267-71. [PMID: 9274889 DOI: 10.1016/s0166-6851(97)00082-0] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- J Gysin
- Unité de Parasitologie Expérimentale, Institut Pasteur de Lyon, Domaine du Poirier, Lentilly, France.
| | | | | | | | | |
Collapse
|
30
|
Abstract
Thrombomodulin (TM), an endothelial receptor for thrombin, endowed with a powerful anticoagulant activity, plays an important role in the antithrombogenicity of the vascular endothelium. Its presence within the human renal glomerulus is already known but was thought to be only endothelial. We looked for TM expression in human mesangial cells (MC), both in situ, in freshly prepared glomeruli, and in primary culture. Both fresh and cultured MC were strongly reactive for TM by immunocytochemical methods. Total TM antigen measured on MC lysates and surface TM activity on MC were 0.292 +/- 0.075 ng/mg of cellular proteins and 1.20 +/- 0.02 pmole of activated protein C/min/mg of cellular proteins, respectively. As shown by the presence of numerous transcripts detected by in situ hybridization, TM was shown to be synthesized by MC in vivo and in culture. The synthesis of active TM by both endothelial and mesangial cells within the renal glomerulus stresses the importance of its role in maintaining renal hemostatic equilibrium, and sheds some light on the conflicting reports of TM over- and underexpression in glomerulopathies to open a new field for investigation.
Collapse
Affiliation(s)
- A Pruna
- Service de Néphrologie, Hôpital Foch, Suresnes, France
| | | | | | | |
Collapse
|
31
|
Affiliation(s)
- M Berard
- INSERM Unité 353, Hôpital St-Louis, Paris, France
| | | |
Collapse
|
32
|
Senet P, Peyri N, Berard M, Dubertret L, Boffa MC. Thrombomodulin, a functional surface protein on human keratinocytes, is regulated by retinoic acid. Arch Dermatol Res 1997; 289:151-7. [PMID: 9128763 DOI: 10.1007/s004030050171] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Thrombomodulin, a major anticoagulant proteoglycan of the endothelial cell membrane, is a thrombin receptor that acts as a cofactor for protein C activation. It has previously been shown that thrombomodulin, present in human epidermis and in lysates of cultured keratinocytes, is implicated in cellular differentiation during mouse fetal development. The role of retinoic acid in keratinocyte differentiation prompted us to study retinoic acid regulation of thrombomodulin expression in primary cultures of keratinocytes isolated from adult human skin, grown at low (undifferentiated keratinocytes) and normal calcium levels (differentiated keratinocytes). Thrombomodulin antigen levels and total and surface activities were measured in cultures without and with retinoic acid. Thrombomodulin mRNA visualized by in situ hybridization was quantified by computer-based image analysis. Functional thrombomodulin was expressed on the surface and in the cytoplasm of cultured human keratinocytes regardless of the calcium concentration. In contrast, retinoic acid induced significant increases in the total antigen level and in surface and intracellular thrombomodulin activities only in keratinocytes grown in a low-calcium medium. In these undifferentiated keratinocytes, quantification of mRNA transcripts showed a threefold increase after retinoic acid stimulation. Thus, functional thrombomodulin is a human keratinocyte surface protein whose expression is controlled through the keratinocyte differentiation program and is modulated in vitro by retinoic acid.
Collapse
Affiliation(s)
- P Senet
- INSERM Unité 353, Hôpital Saint-Louis, Paris, France
| | | | | | | | | |
Collapse
|
33
|
Abstract
Thrombomodulin (TM) is a proteoglycan present on the surface of endothelial and mesothelial cells where it acts as a strong anticoagulant. TM is also located in other cells (keratinocytes, osteoblasts, mononuclear phagocytes...) where it might be involved in cell differentiation or inflammatory processes. The damage of endothelial cells releases cleavage fragments. Plasma TM appears to be a marker of endothelium damage. Plasma TM has been investigated in several disorders: it is usually increased in the case of diffuse endothelial damage.
Collapse
Affiliation(s)
- M Karmochkine
- Service de médecine interne, hôpital de la Croix-Saint-Simon, Paris, France
| | | |
Collapse
|
34
|
Laroche P, Berard M, Rouquette AM, Desgruelle C, Boffa MC. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol 1996; 106:549-54. [PMID: 8853046 DOI: 10.1093/ajcp/106.4.549] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
To investigate the benefit of assaying for antiphospholipid antibodies (aPA) with different antigenic specificities, sera from 141 patients suspected of having aPA were tested by ELISA for IgG and IgM antibodies directed against the following phospholipids (PL) coated individually or together: cardiolipin, phosphatidylinositol, phosphatidylserine and phosphatidylethanolamine. Nonspecific background optical density (OD) was systematically subtracted from the test OD value. Positive reactions were defined as having an OD greater than the 97th percentile OD distribution obtained with sera from 100 healthy individuals. Although the majority of the 79 detected aPA (89% IgG and 77% IgM) were polyspecific, 11 reacted with a single PL and, moreover, belonged to only one isotype. Seven of these 11 patients presented recurrent fetal losses or thrombotic events. These results suggest that routine use of a mixture of both anionic and zwitterionic PL antigens to coat ELISA plates would better detect aPA involved in suggestive pathologies and enhance the ability to identify patients with these mono- or polyspecific antibodies directed or not against cardiolipin, the current standard.
Collapse
Affiliation(s)
- P Laroche
- Biomedical Diagnostics, Marne-la-Vallée, France
| | | | | | | | | |
Collapse
|
35
|
Boffa MC. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker? Haemostasis 1996; 26 Suppl 4:233-43. [PMID: 8979129 DOI: 10.1159/000217304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- M C Boffa
- INSERM U 353, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
36
|
Goudemand J, Boffa MC. Monitoring oral anticoagulation in patients with "strong" lupus anticoagulant. Present situation in France. Ann Med Interne (Paris) 1996; 147 Suppl 1:36-7. [PMID: 8952759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J Goudemand
- Laboratoire d'Hématologie, CHRU, Lille, France
| | | |
Collapse
|
37
|
Boffa MC, Piette JC. Questions-answers about antiphospholipid-protein antibodies and the "antiphospholipid antibody syndrome". Ann Med Interne (Paris) 1996; 147 Suppl 1:54-6. [PMID: 8952766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- M C Boffa
- INSERM U 353, Hôpital Saint-Louis, Paris, France
| | | |
Collapse
|
38
|
Boffa MC, Berard M, Sugi T, McIntyre JA. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J Rheumatol Suppl 1996; 23:1375-9. [PMID: 8856616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To study the requirement for serum and for low (LMWK) and high molecular weight kininogen (HMWK) and/or HMWK binding proteins to detect antiphosphatidylethanolamine antibodies (aPE) in ELISA. METHODS Eighteen patients with aPE (9 IgG and 13 IgM) as the only antiphospholipid antibody (aPL) detected by ELISA were assigned to 4 groups: thromboembolic episodes (TEE) (Group I, n = 6); livedo reticularis (LR) without TEE, (Group II, n = 4); both LR and thrombosis (Group III, n = 4); and systemic lupus erythematosus (SLE) or primary antiphospholipid syndrome (APS) (Group IV, n = 4). All sera were analyzed in ELISA with and without bovine serum and with a purified chromatographic fraction containing LMWK, HMWK, and HMWK binding proteins. RESULTS Eleven aPE were serum dependent: mostly IgG (7/9) and some IgM (4/13). Among the 11 serum dependent aPE, all the 7 IgG and 2 IgM were kininogen reactive. Some serum independent IgM were better detected in the absence than in the presence of serum in the ELISA. CONCLUSION In the 18 patients, kininogens and/or HMWK binding proteins served as a "cofactor" significantly more often for aPE IgG than for aPE IgM (p = 0.007). Kininogen dependent aPE Ig were observed more often in patients with LR with or without TEE (6/8) than in those with SLE or primary APS (0/4) but this difference merely tended to significance (p = 0.06). In 2 patients, one with TEE, the other with primary APS, the IgM aPE was dependent on a serum "cofactor" that was not kininogen.
Collapse
Affiliation(s)
- M C Boffa
- Unité INSERM U353, Hôpital St-Louis, Paris, France
| | | | | | | |
Collapse
|
39
|
Abstract
BACKGROUND Long-standing pulmonary hypertension (PH) leads to structural alterations of the pulmonary vasculature and its endothelium, and occlusion of small vessels by microthrombi. In patients with PH, the search for factors inducing or worsening endothelium damage and in situ thrombi is still ongoing. Thrombomodulin (TM), an endothelial cell membrane protein, is a receptor for thrombin and a major anticoagulant proteoglycan. PURPOSE To analyze plasma TM levels in patients with different forms of severe PH. PATIENTS We prospectively studied 32 consecutive patients with PH referred for heart, lung, or heart-lung transplantation: 11 patients with primary PH (group 1), 11 patients with secondary precapillary PH (Eisenmenger's syndrome, group 2) and 10 patients with secondary postcapillary PH due to congestive heart failure (group 3). Thirty-eight healthy subjects were also studied as a control group. METHODS Plasma concentrations of TM were measured by an immunoenzymatic technique that uses two anti-TM monoclonal antibodies that have a strong avidity and react with different epitopes of the molecule. RESULTS Thrombomodulin plasma levels decreased in all patients with precapillary PH, and this decrease was highly significant compared with controls (26 +/- 2 versus 44 +/- 2 ng/mL, P = 0.0001). In primary PH, the TM decrease was only significant in males whereas in the Eisenmenger's syndrome TM values were the lowest of all the patients studied, with mean values twice as low as controls (22 +/- 2 versus 44 +/- 2 ng/mL, P = 0.0001). In contrast, in postcapillary PH, studied only in males, TM levels were increased (85 +/- 17 versus 54 +/- 3 ng/mL, P = 0.02). Patients with precapillary PH had more severe disease than patients with postcapillary PH, with higher pulmonary artery pressure and pulmonary vascular resistance (P < 0.001). There was no correlation between TM plasma levels and all hemodynamic variables. CONCLUSION We found low levels of plasma TM in patients with precapillary PH but not in postcapillary PH compared with healthy controls. This may be related to the severity of PH and may contribute to the initiation or worsening of in situ thromboses frequently found in pulmonary hypertension. Further studies should analyze whether other markers of endothelial cell damage are correlated with plasma TM levels in patients with precapillary pulmonary hypertension.
Collapse
Affiliation(s)
- P Cacoub
- Department of Internal Medicine, Hopital La Pitié-Salpétrière, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23:1369-74. [PMID: 8856615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To detect antiphosphatidylethanolamine antibodies (aPE) as the only antiphospholipid antibodies (aPL) in 122 patients we investigated for aPL and to correlate the presence of aPL with clinical manifestations. METHODS Patients with autoimmune diseases (n = 41), thromboembolic episodes (TEE) (n = 34), livedo reticularis (LR) without (n = 17) or with (n = 14) thrombosis or recurrent fetal losses (RFL), systemic vasculitides (n = 10), and miscellaneous disorders (n = 6) were investigated for antibodies directed against 4 anionic phospholipids (PL) (cardiolipin, phosphatidylserine, inositol, phosphatidic acid) and lupus anticoagulant (LAC) and then for aPE by modified ELISA. RESULTS 15 patients had aPE and no antibodies to anionic PL including LAC. 7 had IgM, 4 had IgG plus IgM, and 4 had IgG. These aPE were significantly more often associated with TEE alone, with TEE and LR, or with LR alone (p = 0.004) than with autoimmune diseases. CONCLUSION The detection of aPE as the sole aPL in one patient with mesenteric infarcts and RFL led to the diagnosis of primary antiphospholipid syndrome. Followup of 3 patients showed that aPE cannot be considered as transient autoantibodies. Therefore, patients whose clinical symptoms suggest antiphospholipid syndrome but whose sera are negative for antibodies to cardiolipin or another anionic PL should be screened for aPE, particularly patients with thrombosis, RFL, and/or LR.
Collapse
Affiliation(s)
- M Berard
- Unité INSERM U353, Hôpital St Louis, Paris, France
| | | | | | | |
Collapse
|
41
|
Karmochkine M, Mazoyer E, Marcelli A, Boffa MC, Piette JC. High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Haemost 1996; 75:971. [PMID: 8822595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
42
|
Affiliation(s)
- M C Boffa
- Inserm U 353, hôpital Saint-Louis, Paris, France
| |
Collapse
|
43
|
Karmochkine M, Cacoub P, Dorent R, Laroche P, Nataf P, Piette JC, Boffa MC, Gandjbakhch I. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996; 23:286-90. [PMID: 8882033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To assess prevalence and clinical associations of various antiphospholipid antibodies (aPL) in patients with primary and secondary pulmonary hypertension. METHODS A prospective trial of aPL in 38 consecutive patients with pulmonary hypertension. Nine patients had primary pulmonary hypertension. Twenty-nine patients had pulmonary hypertension secondary to different etiologies: left heart failure, 8; congenital heart defect, 11; various lung diseases, 10. The search for aPL directed against 4 phospholipids (cardiolipin, phosphatidylserine, inositol, ethanolamine) was by ELISA. RESULTS Eleven patients (29%) had aPL, with various phospholipid specificities. Mean pulmonary artery pressure and mean pulmonary vascular resistance of aPL positive patients were not different from those of aPL negative patients. Mean pulmonary wedge pressure was significantly lower in aPL positive patients than those without aPL. Positive aPL were detected only in patients with precapillary pulmonary hypertension (11/30; 36.6%). The prevalence of aPL in primary (4/9; 44%) was not significantly different from aPL in secondary (7/29; 24%) pulmonary hypertension. There was no association between the presence of aPL and prior thrombosis or recurrent fetal losses. CONCLUSION The frequent positivity of aPL in precapillary pulmonary hypertension, irrespective of its cause and severity, suggests the existence of an associated endothelial disease. These antibodies might play a role in the initiation and/or progression of in situ thromboses frequently observed in precapillary pulmonary hypertension. Our results reinforce the necessity of longterm anticoagulant treatment in these patients.
Collapse
Affiliation(s)
- M Karmochkine
- Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Piette JC, Papo T, Amoura Z, Boffa MC. [Antiphospholipid antibody/cofactors. What are they? Why, when and how to search for them? Is treatment justified?]. Ann Med Interne (Paris) 1996; 147:492-7. [PMID: 9092360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Antiphospholipid antibodies are a wide family of antibodies, dominated by lupus anticoagulant (LA) and anti-cardiolipin antibodies (aCL), encountered in various circumstances. Unnecessary laboratory tests can be avoided by carefully weighing the indications, especially regarding patient age. Three steps are required to demonstrate LA: screening, mixing studies, then confirmation by neutralization tests. Two coagulation tests at least should be performed aCL are detected with ELISA kits using plates coated with cardiolipin. Due to the large number of kits available and to the lack of agreement on cut-off values, all laboratories must indicate their own standards. Other kits use plates coated with a mixture of phospholipids. Recent data suggest that pathogenic aPL are more specifically directed against phospholipid-associated proteins rather than towards phospholipids. In the future, tests for aCL might be replaced by tests for beta 2-glycoprotein I. The presence of aPL requires a specific treatment only in patients presenting clinical manifestations thought to be aPL-induced (thromboses, fetal losses). Long term warfarin aimed at an INR of 3-3.5 is effective for the secondary prevention of thrombosis. In primary APS, prevention of recurrent miscarriages is frequently achieved by a combination of subcutaneous heparin plus aspirin.
Collapse
Affiliation(s)
- J C Piette
- Service de Médecine Interne, Groupe Hospitalier Pitié-Salpêtrière, Paris
| | | | | | | |
Collapse
|
45
|
Assier H, Chosidow O, Piette JC, Boffa MC, Youinou P, Thomas L, Caux F, Cribier B, Bonnet-Blanc JM, Guillet G. Absence of antiphospholipid and anti-endothelial cell antibodies in malignant atrophic papulosis: a study of 15 cases. J Am Acad Dermatol 1995; 33:831-3. [PMID: 7593788 DOI: 10.1016/0190-9622(95)91843-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- H Assier
- Department of Internal Medicine, Hôpital de la Pitié-Salpêtrière, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bessis D, Sotto A, Viard JP, Bérard M, Ciurana AJ, Boffa MC. Trousseau's syndrome with nonbacterial thrombotic endocarditis: pathogenic role of antiphospholipid syndrome. Am J Med 1995; 98:511-3. [PMID: 7733133 DOI: 10.1016/s0002-9343(99)80355-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- D Bessis
- Hôpital Saint-Eloi, Montpellier, France
| | | | | | | | | | | |
Collapse
|
47
|
|
48
|
Boffa MC, Berard M, Karmochkine M. Heterogeneity of antiphospholipid antibodies and their cofactors. Clin Rev Allergy Immunol 1995; 13:101-6. [PMID: 7648344 DOI: 10.1007/bf02772253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- M C Boffa
- INSERM U 353, Hôpital Saint-Louis, Paris, France
| | | | | |
Collapse
|
49
|
Karmochkine M, Piette JC, Mazoyer E, Wechsler B, Chérin P, Herson S, Godeau P, Boffa MC. [Antiphospholipid antibodies: cause of thrombosis or an epiphenomenon?]. Presse Med 1995; 24:267-70. [PMID: 7899382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Antiphospholipid antibodies (aPL) present in systemic lupus erythematosus and the primary antiphospholipid syndrome are a well-known risk factor for thrombosis. Most of them require the presence of a cofactor, beta 2-glycoprotein I for anticardiolipin antibodies, prothrombin for lupus anticoagulant. These aPL are of the "immune" type. APL are also found in various non-immunological conditions, in which repeated endothelial or membranous damages appear to be frequent, but thromboses are rare. Most of these aPL are cofactor-independent, except those induced by chlorpromazine, and might belong to "natural" antibodies.
Collapse
Affiliation(s)
- M Karmochkine
- Service de Médecine interne, CHU Pitié-Salpêtrière, Paris
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Antiphospholipid antibodies (aPLA) were discovered during the course of Mediterranean spotted fever (MSF) caused by Rickettsia conorii and characterized by endothelial cell (EC) damage resulting from this organism's tropism for EC. In two MSF patients, two types of aPLA were identified: antiphosphatidylethanolamine antibodies detected by immunological methods and lupus anticoagulant detected by clotting assays. The persistence of both aPLA for several months after the acute phase and clinical recovery might correspond to a durable immunological response to membrane damage of EC caused by R. conorii. Their possible role in the pathophysiology of microthrombi formation observed during MSF remains to be elucidated in a study on a larger number of patients.
Collapse
Affiliation(s)
- A Sotto
- Service de Médecine Interne B, Hôpital Carémeau, Nîmes, France
| | | | | | | | | | | |
Collapse
|